Investment Summary

HUTCHMED (China) Limited is an innovative, commercial-stage biopharmaceutical company focused on the discovery, global development and commercialisation of targeted therapies and immunotherapies for cancer and immunological diseases. Headquartered in Hong Kong with major operations in Shanghai, the company has built one of the deepest oncology pipelines among biopharmaceutical companies originating in China, including approved products, advanced clinical Assets and a continued discovery engine. With an expanding international footprint, strategic partnerships with global pharmaceutical leaders and accelerating commercialisation in China, we view HUTCHMED as well placed to deliver meaningful value over the medium term. The shares are rated a Buy.

Business Overview

HUTCHMED operates an integrated platform spanning drug discovery, clinical development, commercial Manufacturing and commercialisation. The company is listed in Hong Kong, on the London AIM market and on the Nasdaq Global Select Market in the United States, providing wide investor access. The portfolio is anchored by Fruquintinib, an oral inhibitor of vascular endothelial growth Factor receptors, which is approved for metastatic colorectal cancer in China and in additional geographies through Partnership with Takeda; Surufatinib, a tyrosine kinase inhibitor approved in pancreatic and non-pancreatic neuroendocrine tumours; and Savolitinib, a MET inhibitor partnered with AstraZeneca and approved for MET-mutated non-small-cell lung cancer in China. Additional approved products and clinical-stage assets target a broad set of cancers and immune-mediated diseases.

HUTCHMED's commercial reach within China is supported by a dedicated oncology field force, partnerships with hospitals and prescribers, and active engagement with reimbursement authorities. Internationally, the company partners with global leaders such as AstraZeneca, Takeda and others to maximise the value of its assets in major markets.

Sector Backdrop

China is one of the largest and fastest-growing pharmaceutical markets globally. Cancer incidence is high and rising, with approximately one in four global new cancer cases occurring in China. National Reimbursement Drug List expansion has accelerated patient access to innovative oncology therapies, while regulatory reforms have shortened approval times and aligned standards more closely with international authorities. At the same time, the global oncology market continues to grow rapidly, supported by the rise of targeted therapies, immuno-oncology, antibody-drug conjugates and cell therapies. Companies that combine local Chinese commercial reach with internationally relevant assets are particularly well positioned to capture value across multiple geographies. HUTCHMED's strategy of in-China commercialisation paired with global partnership-led ex-China rollouts is aligned with these dynamics.

Investment Thesis

Our positive view rests on several pillars. First, Fruquintinib is now a global oncology Brand with approvals in the United States, Europe, Japan, China and other markets, driving meaningful Royalty income from Takeda alongside HUTCHMED's own commercial activities. Second, the broader portfolio of approved products generates a growing Revenue base within China, supported by NRDL inclusion. Third, the pipeline contains multiple high-potential assets in oncology and immunology, providing ongoing news flow. Fourth, the company has a strong Balance Sheet, supported by partnership receipts and Capital raises, providing flexibility to invest in R&D and commercialisation. Fifth, ongoing operational efficiency initiatives are improving the cost structure and supporting the path to sustained profitability. Sixth, the valuation embeds limited Credit for the late-stage pipeline and continued international monetisation.

Growth Drivers

Fruquintinib's global commercialisation through Takeda is a major growth driver. Approvals across the United States, the European Union, Japan and other markets, supported by inclusion in clinical guidelines for advanced colorectal cancer, expand the addressable patient population significantly. HUTCHMED receives a combination of milestone payments and royalties tied to global sales. Within China, Fruquintinib continues to expand into additional indications, including in combination with immuno-oncology and chemotherapy regimens, and across different lines of therapy. Surufatinib penetration continues in neuroendocrine tumours and other indications under investigation. Savolitinib provides additional growth through ongoing partnered development in lung cancer and other solid tumours where MET alterations are present.

The next wave of catalysts includes data readouts and potential filings for Sovleplenib, an oral SYK inhibitor for immune thrombocytopenia and warm autoimmune haemolytic anaemia; Tazemetostat in epithelioid sarcoma and other tumours via licensing; HMPL-306, a dual IDH1/2 inhibitor in acute myeloid leukaemia; HMPL-453, an FGFR inhibitor; and earlier-stage assets in immuno-oncology combinations. Together, these provide multi-year visibility on pipeline momentum.

China's National Reimbursement Drug List inclusion has been a key value driver for HUTCHMED's marketed products. By securing reimbursed status, the company has been able to expand patient access dramatically across hospitals and oncology centres throughout China, while accepting some price concessions in return for higher volumes. The combination of NRDL coverage, hospital listing expansion and oncology guideline inclusion has enabled the company's products to reach a meaningful share of eligible patients. Future expansion of these products into additional cancer indications, combination regimens and earlier lines of therapy continues to provide incremental in-China growth alongside the international momentum delivered through Takeda and other partners.

Financial Performance

HUTCHMED has been moving towards a self-sustaining financial profile, supported by growing in-China product sales, royalties from international partnership milestones and ongoing cost discipline. Revenue has grown rapidly with the launch of Fruquintinib internationally and the expansion of commercial activities in China. The company has been investing significantly in R&D, particularly in late-stage trials supporting global registration of multiple assets. Operating losses have been narrowing as commercial revenue grows and the company benefits from focused investment in highest-conviction pipeline assets. Cash reserves remain strong, with management indicating that current Liquidity is sufficient to fund operations through to projected sustainable profitability. Strategic partnerships continue to provide meaningful non-dilutive capital.

The strengthening financial profile reflects multiple drivers operating concurrently. International product sales of Fruquintinib via Takeda are scaling rapidly, with the brand performing strongly across the United States, the European Union, Japan and additional markets. In-China sales of HUTCHMED's broader portfolio continue to grow through expanded indications and ongoing hospital listing progress. Royalty revenue, which carries very high incremental margins, is growing as a proportion of total revenue. R&D investment intensity remains elevated as the company progresses multiple late-stage programmes, but is increasingly funded by Cash Flow from product sales rather than purely from Equity capital. As this trajectory continues, the company is expected to reach adjusted operating breakeven and beyond, providing a meaningful inflection point for the financial profile.

Pipeline and Clinical Outlook

The HUTCHMED pipeline includes both internally discovered assets and selectively in-licensed programmes. The development strategy combines China-focused trials supporting NMPA approval with multi-regional trials supporting FDA, EMA, MHLW and other registrations. Key Phase III programmes span colorectal cancer, gastric cancer, lung cancer, hepatocellular carcinoma, neuroendocrine tumours, acute myeloid leukaemia and immune thrombocytopenia. Earlier-stage programmes include FGFR-targeted therapies, novel immuno-oncology combinations, ERK and IDH inhibitors and other targeted therapies. The company's discovery engine continues to identify additional clinical candidates. The combination of multiple late-stage assets, internationally relevant data and global partnership infrastructure provides confidence in long-term value creation.

Commercialisation Outlook

HUTCHMED has built one of the most experienced oncology commercial organisations among Chinese biotech companies, with a dedicated field force, medical affairs team, market access and key account capabilities. This allows the company to drive product uptake across leading hospitals, NRDL-listed cancer treatments and integrated oncology centres. Beyond China, HUTCHMED relies on partner organisations such as Takeda for Fruquintinib and AstraZeneca for Savolitinib to commercialise in international markets, complemented by HUTCHMED's own clinical and medical affairs presence in selected regions. The combination of in-China execution and global partnership-led commercialisation provides an efficient and capital-light international expansion model.

Strategic Partnerships

Strategic collaborations are a cornerstone of HUTCHMED's strategy. The partnership with Takeda on Fruquintinib provides not only commercial Leverage outside China but also substantial milestone and royalty potential. The partnership with AstraZeneca on Savolitinib in non-small-cell lung cancer leverages AstraZeneca's global oncology infrastructure. Additional partnerships include those with Lilly, Innovent and others on combination studies. The company continues to evaluate selective in-licensing of complementary assets to broaden its portfolio while preserving capital. Strategic discipline in partnership selection has been a key driver of value creation to date.

Valuation Perspective

HUTCHMED's Enterprise value reflects the success of the Fruquintinib launch and the broader portfolio, but in our view does not fully capture the long-term value embedded in the late-stage pipeline, expanding international royalties and ongoing commercial growth in China. Sum-of-the-parts analysis incorporating Risk-adjusted contributions from Fruquintinib globally, Surufatinib, Savolitinib, the late-stage pipeline and partnership Economics points to material upside from current levels. As pipeline catalysts materialise and the company moves towards sustainable profitability, the shares should re-rate.

Key Risks

Risks include clinical trial outcomes, regulatory approvals across multiple geographies, NRDL pricing dynamics in China, competitive intensity in oncology, foreign exchange and geopolitical considerations. Macro factors including evolving US-China relations, Capital Markets sentiment for Chinese biotechs and currency Volatility may affect share price performance. The company's listings across multiple exchanges introduce some complexity in Capital Structure and reporting. Successful execution of the international commercialisation strategy depends both on partner performance and continued internal R&D delivery.

Sustainability and ESG

HUTCHMED's contribution to cancer care, particularly through innovative therapies developed within China and now available globally, aligns with broader healthcare access objectives. The company emphasises responsible research, ethical conduct of Clinical Trials, patient support and continued investment in scientific talent. ESG positioning is supported by strong governance, transparent reporting and ongoing engagement with regulators, patients, healthcare professionals and investors. The company has also been investing in patient assistance programmes within China to expand affordability for patients without comprehensive insurance coverage, demonstrating a commitment to expanding the practical reach of its medicines beyond the limits of reimbursement frameworks alone.

Management and Scientific Leadership

HUTCHMED's leadership team combines deep oncology and pharmaceutical industry experience with a strong scientific foundation. CEO Weiguo Su and his colleagues have built one of the most respected pharmaceutical R&D organisations in China, with a particular focus on internally discovered small molecule targeted therapies. The scientific philosophy emphasises rigorous target validation, drug-like chemistry, robust preclinical and translational science and well-designed clinical programmes that can support both China NMPA and international regulatory approvals. The integration of in-China scale with internationally competitive science differentiates HUTCHMED from many domestic peers. A strong board, deep relationships with multinational partners and a culture of scientific rigour underpin the long-term value proposition.

Importantly, HUTCHMED has been transitioning from a research-intensive biotech towards a commercially self-sustaining biopharmaceutical company. The successful international rollout of Fruquintinib via Takeda has been a transformational moment, validating both the science and the business model. As the company continues to expand its in-China commercial scale and benefits from a rising royalty stream from international sales, the financial profile is becoming progressively more attractive. This transition is a key element of the medium-term investment thesis and supports our positive view on the shares.

Conclusion: Why We Rate HUTCHMED a Buy

HUTCHMED (China) Limited offers a distinctive opportunity to invest in a commercially successful, globally relevant Chinese oncology biopharmaceutical company. With Fruquintinib delivering meaningful international revenue, a deep late-stage pipeline, strong partnerships, expanding China commercial scale and a path to sustainable profitability, the long-term outlook is compelling. The current valuation provides an attractive entry point. We therefore rate HUTCHMED (China) Ltd a Buy. Investors seeking exposure to the broader China healthcare growth opportunity, combined with internationally relevant oncology innovation, should find the stock particularly compelling at current levels.